Discovering innovative small molecule therapeutics against novel cancer targets
Focusing on emerging fields of innate immunity, synthetic lethality, and RNA modulation
About 858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. Its lead programs focus on the emerging fields of innate immunity, synthetic lethality, and RNA modulation.
858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies.
858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.
3115 Merryfield Row, Suite 110
San Diego, CA 92121